CA125, the most widely used ovarian cancer biomarker, was first identified approximately 35 years ago in an antibody screen against ovarian cancer antigen. Two decades later, it was cloned and characterized to be a transmembrane mucin, MUC16. Since then, several studies have investigated its expression, functional, and mechanistic involvement in multiple cancer types. Antibodybased therapeutic approaches primarily using antibodies against the tandem repeat domains of MUC16 (e.g., oregovomab and abagovomab) have been the modus operandi for MUC16-targeted therapy, but have met with very limited success. In addition, efforts have been also made to disrupt the functional cooperation of MUC16 and its interacting partners; for example, use of a novel immunoadhesin HN125 to interfere MUC16 binding to mesothelin. Since the identification of CA125 to be MUC16, it is hypothesized to undergo proteolytic cleavage, a process that is considered to be critical in determining the kinetics of MUC16 shedding as well as generation of a cell-associated carboxyl-terminal fragment with potential oncogenic functions. In addition to our experimental demonstration of MUC16 cleavage, recent studies have demonstrated the functional importance of carboxyl terminal fragments of MUC16 in multiple tumor types. Here, we provide how our understanding of the basic biologic processes involving MUC16 influences our approach toward MUC16-targeted therapy. Cancer Res; 75(22); 4669-74. Ó2015 AACR.
Introduction
MUC16 is a type I transmembrane mucin that was cloned and characterized independently by Lloyd and O'Brien in an effort toward biochemical characterization of CA125 (1) (2) (3) . On the basis of the sequencing data, MUC16 is an extremely large glycoprotein (22, 152 amino acids) with approximately 12,000 amino acids of the heavily O-glycosylated N-terminal region, a tandem repeat region comprising approximately 60 repeats of 156 amino acids each, a transmembrane domain and a cytoplasmic tail of 32 amino acids ( Fig. 1A ; ref. 4) . MUC16 harbors 56 SEA (sea urchin, enterokinase, and agrin) domains, the highest among all mucins, and each SEA domain constitutes a major portion (amino acids 1-128) of each tandem repeat (Fig. 1A , black outlined box at the bottom left; ref. 5) . MUC16 is predicted to undergo cleavage in the penultimate and/or last SEA domain and phosphorylation event(s) in the cytoplasmic tail domain (CTD) is (are) believed to be critical determinants of its cleavage (1, (6) (7) (8) . Likewise, existence of splice forms without a transmembrane domain resulting in the secretory MUC16 has also been predicted (9) . However, proper experimental validation is lacking to support these claims. Although 35 years have elapsed since the discovery of CA125 and 14 years since it was identified to be MUC16, our understanding of the basic biologic processes involving MUC16 cleavage, promoter characterization, and therefore its regulation, existence of splice variants etc. is still rudimentary. Part of the problems in addressing these issues lies with the enormous size and complexity of this protein and lack of appropriate technical resources (such as antibodies for various regions of MUC16) in addressing these problems. In this review, we focus on how our understanding of some of these basic processes (particularly cleavage) affects our outlook in exploiting the therapeutic potential of MUC16.
MUC16: A Historical Perspective
In 1981, Bast and colleagues developed a monoclonal antibody (i.e., OC125) that was reactive against epithelial ovarian cancer cells and cryopreserved tumor tissues from ovarian cancer patients, but not with the nonmalignant tissue samples (10) . The antigen that was reactive to this particular antibody was designated as cancer antigen 125, hence the name CA125. Although the antibody was developed with a therapeutic intent to treat the ovarian cancer patients, shedding of the antigen CA125 in to the circulation did not bode well for that purpose. Instead, detection of the antigen CA125 in the circulation was foreseen as an interesting opportunity to monitor the recurrent ovarian cancer and still is the current gold standard marker for recurrent ovarian cancer. Although the potential of using CA125 toward (i) monitoring the response to ovarian cancer treatment, (ii) recurrence of (12) , regulation of expression (13, 14) , and its functional involvement in health and disease (15) (16) (17) (18) (19) (20) (21) . Recently, Cheon and colleagues generated and characterized a whole body Muc16 knockout mouse model (22) . These mice are viable and fertile with lack of any apparent developmental defects (22) and therefore, can be used as an interesting tool to address the basic questions related to Muc16/MUC16.
MUC16 Cleavage: A Long-Standing Question
Because the molecular identity of CA125 was revealed to be a single pass transmembrane mucin MUC16 (2, 3), predictions have been made about its possible cleavage in the juxta-membrane SEA domains. Primarily, the PLARRVDR site (site #1) in the last (56th; ref. 1) and DSVLV site (site #2, analogous to GSVVV site on MUC1) on the penultimate (55th; ref. 6 ) SEA domains were thought to be major proteolytic sites (Fig. 1A) . However, this remained experimentally untested for more than a decade. Because carboxyl-terminal fragments of transmembrane mucins are hypothesized to be critical in mediating their signaling functions and MUC16 (CA125) being one the most widely used serum biomarker for ovarian cancer (23) and one of the top three frequently mutated gene across many tumor types (24) , it is imperative to understand the cleavage of MUC16 if we are to understand its role in tumorigenesis. One of the major hurdles in addressing MUC16 cleavage has been lack of antibodies for the C-terminal region as most of the well-characterized antibodies bind to the repetitive epitopes (i.e., CA125) in the tandem repeat region. To circumvent the lack of antibodies for the C-terminal MUC16, we used dual epitope tagging of various lengths of carboxyl-terminal MUC16 fragments to narrow down the potential site of cleavage. We observed that earlier predicted sites #1 and #2 are not essential for MUC16 cleavage, instead a novel stretch of 12 amino acids in the juxtamembrane ectodomain (PLTGNSDLPFWA) was found to be sufficient for MUC16 cleavage ( Fig. 1A; ref. 11 ). Although this novel stretch of 12 amino acids was found to be sufficient for MUC16 cleavage, it is not an absolute necessity, as deletion of this stretch did not result in complete abrogation of MUC16 cleavage (11) . It can thus be speculated that MUC16 cleavage may not be entirely dependent on its primary amino acid sequence. Furthermore, MUC16 cleavage was found to be dependent on the acidic pH of the Golgi and/or postGolgi compartment (Fig. 1B) . Using a CTD-swapped variant (MUC16-CTD was replaced with MUC4-CTD), we ruled out any Figure 1 . Implications of basic biologic understanding of MUC16 in cancer therapy. A, schematic representation of full-length MUC16 (with particular emphasis on the juxta-membrane ectodomain cleavage) and a prototype tandem repeat. MUC16 is composed of approximately 22,152 amino acids (aa) with approximately 12,000aa in the N-terminal domain, which is exclusively O-glycosylated. This is followed by 60þ tandem repeats (TR) of approximately 156aa each, of which a major part (approximately 1-128aa) is formed by the sea-urchin, enterokinase, and agrin (SEA) domain. This TR domain is primarily O-glycosylated, but harbors sites of N-glycosylation too. A more detailed schematic of a prototype tandem repeat domain of MUC16 is illustrated within the box (bottom left), with the likely location of the antigenic epitope of CA125 between the two-cysteine residues of the adjacent tandem repeats. Experimental and bioinformatics predictions suggest approximately five O-glycosylation and three N-glycosylation sites within the SEA domain stretch of the TR and approximately ten O-linked glycosylation sites in the linker region. The penultimate (55th, location of site #2) and last (56th, location of site #1) SEA domains of MUC16 were proposed to harbor the proteolytic sites for MUC16; however, they did not turn out to be the true proteolytic sites in our experimental analyses. Instead, a stretch of 12aa (AWFPLDSNGTLP) proximal to the transmembrane (TM) domain was found to be sufficient for proteolytic processing of MUC16. However, it is not absolutely necessary for the cleavage, suggesting possible additional cleavage sites. Previous MUC16-based therapeutic studies using antibodies against the TR region (CA125) of MUC16 were quite unsuccessful. We therefore believe using drug-conjugated antibodies that bind to the juxtamembrane ectodomain region of MUC16 (cell-associated MUC16-Cter) will result in better therapeutic efficiency. The positively charged RRRKK (blue and underlined) motif in the intracellular juxta-membrane region is shown to interact with ezrin-radixin-moesin (ERM) domain containing proteins, which in turn can influence the cytoskeletal proteins, such as actin. Both the lysines in the RRRKK motif in the CTD undergo polyubiquitylation (Ub-n) and the designated tyrosine undergoes c-Src-mediated phosphorylation. Functional significance of these posttranslational modifications is yet to be elucidated. B, proposed model for the proteolytic processing of MUC16. Following transcription, MUC16 protein synthesis is initiated in the endoplasmic reticulum (ER; pH7.1) along with N-linked glycosylation. Further addition of N-linked and O-linked glycosylation takes place as it progresses through the cis-medial-trans Golgi apparatus. In addition, the juxta-membrane ectodomain cleavage of MUC16 takes place en route to the plasma membrane in the acidifying Golgi (pH7.0- involvement of intracellular cues along with the previous claims of cytoplasmic serine and/or threonine phosphorylation-dependent MUC16 cleavage. In addition, involvement of proteases, such as neutrophil elastase and MMP-7, was also ruled out (11) .
Although ours is the first study to experimentally demonstrate the oft-predicted MUC16 cleavage, several important questions are still needed to be answered. First, what is the exact mechanism of MUC16 cleavage? Is it autopreolteolytic or protease dependent? If protease dependent, what protease(s) is (are) involved in its cleavage? Because MUC16 cleavage takes place in the acidic pH of the Golgi and/or post-Golgi compartment and we have ruled out the possibility of intra-membrane cleavage (cleavage by g-secretase, rhomboid protease and site-1/site-2 protease), any protease with low optimum pH would be responsible for its cleavage in case of protease dependency. Second, do the cleaved N-terminal and C-terminal fragments heterodimerize and stay on the cell surface or the N-terminal fragment is shed off the surface (generating circulating CA125) and only the MUC16-Cter stays on the surface (Fig. 1B) ? Third, because MUC16-Cter (without any obvious DNA-binding domain) is localized into the nucleus and is found in the chromatin bound fraction, it is imperative to understand the mechanism of its nuclear translocation and chromatin enrichment (the putative nuclear localization sequence RRRKK is not required for nuclear localization)?
Role of MUC16 (MUC16-Cter) in Tumorigenesis and Metastasis
Although CA125 is widely used as the serum biomarker for ovarian cancer and most of the studies have investigated the role of MUC16 in ovarian cancer, recent studies have shown that MUC16 is overexpressed in multiple tumor types, including breast, pancreatic, and colorectal cancer (25, 26) . In addition, it is found to be one of the top three frequently mutated gene across multiple tumor types (24) . Owing to the clinical importance of MUC16 (CA125) as a biomarker, several studies have attempted to address the functional significance of MUC16 in multiple tumor cells primarily using shRNA-mediated knockdown approach and have been reviewed elsewhere (17) . Because of space constraints, we discuss here the less explored carboxyl-terminal MUC16 and its role in tumorigenesis and metastasis. Because MUC16 was predicted to undergo cleavage in the last and/or penultimate SEA domain, various groups have ectopically expressed different lengths of carboxyl-terminal MUC16 in an attempt to address its functional role. In one of the very first study, Boivin and colleagues ectopically expressed 283 amino acid long carboxyl-terminal fragment of MUC16 in SKOV3 ovarian cancer cells that resulted in reduced sensitivity of MUC16-Cter expressing cells toward cisplatin by attenuating apoptosis (18) . Mechanistically, MUC16-Cter was shown to impart resistance to TRAIL-induced apoptosis by reducing the expression of TRAIL receptor-2 (also known as death receptor DR5) and increasing the expression of cellular FLICE inhibitory protein (cFLIP; ref. 19 ). Subsequently, the same group demonstrated that the 283 amino acids long MUC16-Cter was sufficient to impart enhanced tumorigenic and metastatic properties to SKOV3 cells in vitro and in vivo in a CTD-dependent manner (27) . In another recent study, Akita and colleagues demonstrated enhanced migratory potential of breast and colon cancer cells upon ectopic expression of 413 amino acids long MUC16-Cter fragment (20) . Finally, MUC16-Cter (283 amino acids) was shown to transform NIH3T3 cells in a CTD-dependent manner demonstrating its oncogenic potential (21) .
Although all the above studies addressed the functional significance of carboxyl-terminal MUC16, none of these studies have attempted to substantiate whether MUC16 indeed undergoes cleavage to generate the MUC16-Cter. Using a dual epitope-tagged 114 amino acids long fragment of carboxyl-terminal MUC16, we demonstrated the generation of approximately 17-kDa MUC16-Cter that was capable of imparting tumorigenic and metastatic phenotypes to pancreatic cancer cells in vitro and in vivo (15) . Mechanistically, we demonstrated that MUC16-Cter-mediated nuclear enrichment of JAK2 leads to upregulation of stemness-specific genes, such as LMO2 and NANOG, resulting in accumulation of ALDH þ pancreatic cancer stem-like cells ( Fig. 1C; ref. 15 ). With experimental demonstration of MUC16 cleavage, further basic understanding of the mechanism(s) of the involvement of MUC16-Cter in tumorigenicity and metastasis would be necessary in order for us to devise therapeutic intervention.
MUC16 as a potential therapeutic target
Owing to the clinical importance of CA125, several studies have attempted to target MUC16 therapeutically, primarily using antibodies directed against the tandem repeat domains of MUC16, where the CA125 epitopes have been hypothesized to reside. Use of antibody-based therapeutics, such as oregovomab (a modified murine MAb-B43.13 that binds with high affinity to CA125; ref. 28 ) and abagovomab (an anti-idiotypic antibody produced by mouse hybridoma against CA125; ref. 29) in phase II and III clinical trials against ovarian cancer patients, was met with limited success respectively. One of the major reasons for the failure of these therapies could be attributed to our incomplete understanding of the basic cellular processing of MUC16 such as cleavage (30) . Because these antibodies bind to the circulating (or shed) CA125, it is highly likely that these antibodies do not reach cancer cells. In addition, our lack of understanding of the kinetics and dynamics of MUC16 cleavage thwarts our efforts to prevent MUC16 shedding, which in turn reduces the therapeutic efficacy of these antibodies (30) . Therefore, antibodies against the carboxyl-terminal portion of MUC16 are urgently required. Rao and colleagues generated several monoclonal antibodies targeting the membrane proximal ectodomain and the CTD of MUC16. These antibodies are shown to be effective in multiple applications, therefore, are expected to be useful in diagnostics and therapeutics (31) . However, these antibodies are generated assuming cleavage of MUC16 at PLARRVDR site (site #1), 50 residues upstream of the TM domain and therefore may not be very efficient in binding the cell-associated MUC16-Cter (as 12 residues upstream of the TM domain are sufficient for MUC16 cleavage). Therefore in addition to the above-mentioned antibodies, additional antibodies toward carboxyl-terminal MUC16, including the membrane proximal 12 residues (Fig. 1A) , will be critical for diagnostic and therapeutic targeting using MUC16. The antibodies for the carboxyl-terminal portion of MUC16 that remains associated with the tumor cells can be exploited to design MUC16-based immunotherapeutic modalities such as chimeric antigen receptor (CAR). For example, adoptive transfer of T cells transduced with MUC16-Cter-specific CAR generated using single chain variable fragment (scFv) from the V H and V L chains of the 4H11 antibody against the juxtamembrane ectodomain of MUC16, CD28 transmembrane, and cytoplasmic signaling domain and TCRz cytoplasmic signaling domain (4H11-28z-MUC-CD) into SCID-Beige mice bearing ovarian tumor was shown to be highly effective in killing MUC16-Cter þ ovarian cancer cells (32) . However, further indepth characterization should be carried out to evaluate the therapeutic potential of immunotherapies based on CAR.
Besides antibody-based therapeutics, approaches that interfere with the cleavage of MUC16 offer promising platforms for MUC16-based therapeutics. Preventing cleavage of MUC16 should be considered an alternative approach to the existing MUC16-based therapeutics for two reasons. First, preventing MUC16 cleavage would increase the cell surface representation of MUC16, which will enhance the efficacy of antibody-based therapeutics, such as oregovomab and abagovomab. Second, because nuclear localization of MUC16 is cleavage dependent, abrogation of MUC16 cleavage would reduce the nuclear functions of MUC16-Cter. Because cleavage of MUC16 takes place in the Golgi/post-Golgi compartments, use of a prodrug form of brefeldin-A (Breflate, NSC656202; ref. 33 ) that induces fusion of Golgi to the endoplasmic reticulum, resulting in a rapid and reversible block in the secretory pathway, can be considered an interesting approach to inhibit MUC16 cleavage (Fig. 1B ). An increased reliance of cancer cells on the secretory pathway than their normal counter parts can be exploited to reduce the toxicity of breflate toward normal cells.
Efforts to disrupt the functional cooperation of MUC16 and its interacting partners are viewed as interesting therapeutic intervention in addition to antibody and cleavage based therapeutics. (41) . On the similar line of thoughts, Garg and colleagues generated a meso-TR3 chimera, where the secretory form of mesothelin (devoid of GPI-anchor) was fused on the N-terminal side of TR3 (a genetically fused trimer of TRAIL), a ligand for the activation of death receptor pathway (40) . Mesothelin of Meso-TR3 complex provides specificity toward cancer cells that express MUC16 on the cell surface and subsequent interaction of DR3 with the DRs would lead to killing of cancer cells (Fig. 1C; ref. 40) . Although, HN125 and Meso-DR3 are novel means of targeting MUC16-positive cancer cells, further characterizations using preclinical models would be necessary to validate their therapeutic potential before being tried in clinical trials.
Conclusions and Perspectives
MUC16, besides being the precursor for the most widely used biomarker for recurrent ovarian cancer CA125, has been found to play active role in tumorigenesis and metastasis of ovarian, pancreatic, and breast cancer, etc. In addition, we are only beginning to understand the basic biologic processes and functions of MUC16 such as cleavage, identification of CA125 epitope on MUC16, mechanistic involvement of MUC16-Cter in tumorigenesis and metastasis, etc. However, a thorough and complete understanding of this complex protein in terms of mechanism of cleavage, generation of circulating CA125, nuclear translocation and subsequent gene regulation, identification of protein partners that mediate its functions, effects of posttranslational modifications on its functions and stability, promoter characterization and regulation of its expression, identification of splice variants (if exists) and their context of splicing, etc. would be required to realize the full potential MUC16 in terms of disease diagnostics and therapeutics.
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